Working… Menu
Trial record 8 of 406 for:    BMS-936558

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03743766
Recruitment Status : Recruiting
First Posted : November 16, 2018
Last Update Posted : April 23, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
John Kirkwood, University of Pittsburgh

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : October 2022